TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effective Feedback to Improve Primary Care Prescribing Safety (EFIPPS): a Randomised Controlled Trial Using ePrescribing Data
Brief Summary: We hypothesise that feedback and feedback + psychology informed intervention delivered to primary care medical practices will reduce high-risk prescribing to patients compared to a simple educational intervention alone. The specific objectives are :

1. To test the effectiveness of the two EFIPPS feedback arms in reducing the specified primary outcome of a composite measure of high-risk antipsychotic, non-steroidal anti-inflammatory drug, and antiplatelet drug prescribing
2. To test the effectiveness of the two EFIPPS feedback arms in reducing the specified secondary outcomes of the six individual measures constituting the composite
3. To assess the cost-effectiveness of the intervention


Options:
A: Arm Label: Pharmacist Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Pharmacist Intervention; Assigned to Arm(s): Pharmacist Intervention
B: Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Arm Label: Usual care + feedback of practice performance; Type: ACTIVE_COMPARATOR; Interventions: Other: Feedback of Performance | Arm Label: Usual care + feedback + health psychology intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Feedback of Performance + Health Psychology Informed Intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care | Intervention Type: OTHER; Name: Feedback of Performance; Assigned to Arm(s): Usual care + feedback of practice performance | Intervention Type: OTHER; Name: Feedback of Performance + Health Psychology Informed Intervention; Assigned to Arm(s): Usual care + feedback + health psychology intervention
C: Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care for hospital discharge | Arm Label: intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Medication Information Transfer Intervention | Intervention Type: OTHER; Name: Medication Information Transfer Intervention; Assigned to Arm(s): intervention | Intervention Type: OTHER; Name: Usual care for hospital discharge; Assigned to Arm(s): control
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease | Intervention Type: BEHAVIORAL; Name: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Complex Intervention on Reducing the Prevalence of Smoking Among Adolescents: a Cluster Randomized Control Trial
Brief Summary: In this multicenter cluster randomized controlled trial stratified by school baseline prevalence of smoking will be randomly allocated to the control or intervention group. Control schools will receive normal smoking education and intrvention schools will receive a four year class-based curriculum intervention (22 Classroom lessons), reinforcement of smoke-free school policy, smoking cessation in parents, pupils, and teachers and information and annual meeting with parents.

Study participants will be children aged 12 to 15 years old ; they will be followed to 2 years after high school. External evaluator and analyst will be blinded to school allocation.

The aim of this study is to analyze the effectiveness of a complex intervention to reduce the prevalence of smoking at 3º ESO (14-15 yrs-old) and 2 years after high school (17-18 yrs-old) .


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention, Behavioral: Secondary (Behavioral) Weight Gain Prevention | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Primary (Environmental) Weight Gain Prevention; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BEHAVIORAL; Name: Secondary (Behavioral) Weight Gain Prevention; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Arm 3
B: Arm Label: School-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: School intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: School intervention; Assigned to Arm(s): School-based intervention
C: Arm Label: LA Sprouts intervention; Type: EXPERIMENTAL; Interventions: Behavioral: LA Sprouts intervention | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: LA Sprouts intervention; Assigned to Arm(s): LA Sprouts intervention
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity guidance, Behavioral: Health education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity guidance; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Health education; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study evaluates the effects of different therapies in ovulation induction in Intrauterine Insemination Cycles.


Options:
A: Arm Label: "Individual" or "standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: rFSH drug dose | Arm Label: "Standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: "Standard" rFSH dose | Intervention Type: DRUG; Name: rFSH drug dose; Assigned to Arm(s): "Individual" or "standard" rFSH dose | Intervention Type: DRUG; Name: "Standard" rFSH dose; Assigned to Arm(s): "Standard" rFSH dose
B: Arm Label: Aromatase Inhibitors (AI); Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole (aromatase inhibitor) | Arm Label: Clomiphene Citrate (CC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene Citrate | Arm Label: Follicle Stimulating Hormone (FSH); Type: ACTIVE_COMPARATOR; Interventions: Drug: Follicle Stimulating Hormone (gonadotropin) | Intervention Type: DRUG; Name: Letrozole (aromatase inhibitor); Assigned to Arm(s): Aromatase Inhibitors (AI) | Intervention Type: DRUG; Name: Clomiphene Citrate; Assigned to Arm(s): Clomiphene Citrate (CC) | Intervention Type: DRUG; Name: Follicle Stimulating Hormone (gonadotropin); Assigned to Arm(s): Follicle Stimulating Hormone (FSH)
C: Arm Label: HP-hMG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meropur 150 a day | Arm Label: rFSH plus rLH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gonal-f 150 plus Luveris 150 | Intervention Type: DRUG; Name: Meropur 150 a day; Assigned to Arm(s): HP-hMG | Intervention Type: DRUG; Name: Gonal-f 150 plus Luveris 150; Assigned to Arm(s): rFSH plus rLH
D: Arm Label: Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomifen, Ethinyl Estradiol | Arm Label: human menopausal gonadotropins; Type: ACTIVE_COMPARATOR; Interventions: Drug: Menotropins | Intervention Type: DRUG; Name: Clomifen, Ethinyl Estradiol; Assigned to Arm(s): Tablets | Intervention Type: DRUG; Name: Menotropins; Assigned to Arm(s): human menopausal gonadotropins

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Multi-center, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of the Co-administration of NVA237 + Indacaterol Once Daily vs. Indacaterol Once Daily in Patients With Moderate to Severe COPD
Brief Summary: This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Budesonide/formoterol (Symbicort Turbuhaler) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol (Oxis Turbuhaler) | Intervention Type: DRUG; Name: Budesonide/formoterol (Symbicort Turbuhaler); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol (Oxis Turbuhaler); Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 2
C: Arm Label: NVA237 + indacaterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 50 µg and indacaterol 150 µg | Arm Label: Placebo to NVA237 + indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to NVA237 and indacaterol 150 µg | Intervention Type: DRUG; Name: NVA237 50 µg and indacaterol 150 µg; Assigned to Arm(s): NVA237 + indacaterol | Intervention Type: DRUG; Name: Placebo to NVA237 and indacaterol 150 µg; Assigned to Arm(s): Placebo to NVA237 + indacaterol
D: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Multi-center, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of the Co-administration of NVA237 + Indacaterol Once Daily vs. Indacaterol Once Daily in Patients With Moderate to Severe COPD
Brief Summary: This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease.


Options:
A: Arm Label: Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium/Formoterol | Arm Label: Placebo to Aclidinium/Formoterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium/Formoterol; Assigned to Arm(s): Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo to Aclidinium/Formoterol
B: Arm Label: tiotropium + olodaterol low dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium, Drug: olodaterol | Arm Label: tiotropium + olodaterol high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium, Drug: olodaterol | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol high dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol high dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol low dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol low dose
C: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 125/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 125mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: GW642444 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo only | Intervention Type: DRUG; Name: GSK573719/GW642444 125/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: GSK573719 125mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GW642444 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo only; Assigned to Arm(s): Placebo
D: Arm Label: NVA237 + indacaterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 50 µg and indacaterol 150 µg | Arm Label: Placebo to NVA237 + indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to NVA237 and indacaterol 150 µg | Intervention Type: DRUG; Name: NVA237 50 µg and indacaterol 150 µg; Assigned to Arm(s): NVA237 + indacaterol | Intervention Type: DRUG; Name: Placebo to NVA237 and indacaterol 150 µg; Assigned to Arm(s): Placebo to NVA237 + indacaterol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study of Whether General or Regional Anesthesia for Patients Undergoing Elective Total Knee Arthroplasty Could Effect Length of Hospital Stay
Brief Summary: Patients undergoing elective total knee arthroplasty are randomized to either intrathecal anesthesia, wound infiltration with local anesthetics and standardized postoperative care (NA = neuraxial anesthesia) or general anesthesia, intraoperative glucocorticoids with accelerated postoperative care principles (GA). The study hypothesis is that GA would reduce length-of-hospital stay. Outcome variables are postoperative nausea and vomiting, mobilization rate, pain, requirement of analgesics, and length-of-hospital stay.


Options:
A: Arm Label: Aquamantys; Type: EXPERIMENTAL; Interventions: Device: Aquamantys | Arm Label: Standard of Care: Tourniquet; Type: ACTIVE_COMPARATOR; Interventions: Device: Tourniquet | Intervention Type: DEVICE; Name: Aquamantys; Assigned to Arm(s): Aquamantys | Intervention Type: DEVICE; Name: Tourniquet; Assigned to Arm(s): Standard of Care: Tourniquet
B: Arm Label: Tourniquet; Type: EXPERIMENTAL; Interventions: Device: Tourniquet | Arm Label: No tourniquet; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tourniquet; Assigned to Arm(s): Tourniquet
C: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: General Anesthesia | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Neuraxial anesthesia | Intervention Type: DRUG; Name: General Anesthesia; Assigned to Arm(s): treatment | Intervention Type: DRUG; Name: Neuraxial anesthesia; Assigned to Arm(s): Placebo
D: Arm Label: tourniquet; Type: EXPERIMENTAL; Interventions: Procedure: Total knee arthroplasty | Arm Label: non-tourniquet; Type: EXPERIMENTAL; Interventions: Procedure: Total knee arthroplasty | Intervention Type: PROCEDURE; Name: Total knee arthroplasty; Assigned to Arm(s): non-tourniquet, tourniquet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Building on a Point-of-purchase Intervention to Encourage Healthy Food Choices
Brief Summary: This study builds on the framework of a previously implemented color-coded food labeling intervention in a hospital cafeteria by testing the incremental effectiveness of providing employees with individual feedback and incentives for increasing healthy purchases in a 3-arm randomized controlled trial. The investigators hypothesize that employees assigned to receive feedback will increase healthy purchases more than employees who receive no contact and that employees who receive feedback plus incentives will increase healthy purchases more than those who receive feedback alone.


Options:
A: Intervention Type: BEHAVIORAL; Name: attitude change; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: adiposity prevention program; Assigned to Arm(s): N/A
B: Arm Label: Sugar-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Sugar-sweetened soft drink | Arm Label: Aspartame-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Aspartame-sweetened soft drink | Arm Label: Semi-skimmed milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Semi-skimmed milk | Arm Label: Water; Type: PLACEBO_COMPARATOR; Interventions: Other: Water | Intervention Type: OTHER; Name: Sugar-sweetened soft drink; Assigned to Arm(s): Sugar-sweetened soft drink | Intervention Type: OTHER; Name: Aspartame-sweetened soft drink; Assigned to Arm(s): Aspartame-sweetened soft drink | Intervention Type: OTHER; Name: Semi-skimmed milk; Assigned to Arm(s): Semi-skimmed milk | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water
C: Arm Label: Healthy Eating + Eco-Friendly Campaign; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Eating + Eco-Friendly Campaign | Arm Label: Healthy Eating Campaign; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Eating Campaign | Arm Label: Control/Delayed Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy Eating + Eco-Friendly Campaign; Assigned to Arm(s): Healthy Eating + Eco-Friendly Campaign | Intervention Type: BEHAVIORAL; Name: Healthy Eating Campaign; Assigned to Arm(s): Healthy Eating Campaign
D: Arm Label: Feedback only; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback letters | Arm Label: Feedback plus incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback plus incentives | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feedback letters; Assigned to Arm(s): Feedback only | Intervention Type: BEHAVIORAL; Name: Feedback plus incentives; Assigned to Arm(s): Feedback plus incentives

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Brief Summary: This study was to assess the safety and efficacy of sofosbuvir in combination with ribavirin (RBV) administered for 12 or 16 weeks in participants with genotypes 2 or 3 hepatitis C virus (HCV) infection as assessed by the proportion of participants with sustained virologic response (SVR) 12 weeks after discontinuation of therapy (SVR12).


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: ANA598 200 mg bid or placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: ANA598 400 mg bid or placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: ANA598 800 mg bid or placebo | Intervention Type: DRUG; Name: ANA598 200 mg bid or placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: ANA598 400 mg bid or placebo; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: ANA598 800 mg bid or placebo; Assigned to Arm(s): Cohort 3
B: Arm Label: Genotype 2 treatment-naive; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: Genotype 2/3 treatment-experienced; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: Genotype 1/3/4 treatment-naive; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Genotype 1/3/4 treatment-naive, Genotype 2 treatment-naive, Genotype 2/3 treatment-experienced | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Genotype 1/3/4 treatment-naive, Genotype 2 treatment-naive, Genotype 2/3 treatment-experienced
C: Arm Label: LDV/SOF (treatment naive); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV (treatment naive); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF (treatment experienced); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV (treatment experienced); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF (treatment experienced), LDV/SOF (treatment naive), LDV/SOF+RBV (treatment experienced), LDV/SOF+RBV (treatment naive) | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV (treatment experienced), LDV/SOF+RBV (treatment naive)
D: Arm Label: SOF+RBV+placebo; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV, Drug: Placebo to match SOF, Drug: Placebo to match RBV | Arm Label: SOF+RBV; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV, SOF+RBV+placebo | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV, SOF+RBV+placebo | Intervention Type: DRUG; Name: Placebo to match SOF; Assigned to Arm(s): SOF+RBV+placebo | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): SOF+RBV+placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Brief Summary: This study was to assess the safety and efficacy of sofosbuvir in combination with ribavirin (RBV) administered for 12 or 16 weeks in participants with genotypes 2 or 3 hepatitis C virus (HCV) infection as assessed by the proportion of participants with sustained virologic response (SVR) 12 weeks after discontinuation of therapy (SVR12).


Options:
A: Arm Label: Genotype 2 treatment-naive; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: Genotype 2/3 treatment-experienced; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: Genotype 1/3/4 treatment-naive; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Genotype 1/3/4 treatment-naive, Genotype 2 treatment-naive, Genotype 2/3 treatment-experienced | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Genotype 1/3/4 treatment-naive, Genotype 2 treatment-naive, Genotype 2/3 treatment-experienced
B: Arm Label: LDV/SOF 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF 12 weeks, LDV/SOF 24 weeks, LDV/SOF+RBV 12 weeks, LDV/SOF+RBV 24 weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV 12 weeks, LDV/SOF+RBV 24 weeks
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: ANA598 200 mg bid or placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: ANA598 400 mg bid or placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: ANA598 800 mg bid or placebo | Intervention Type: DRUG; Name: ANA598 200 mg bid or placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: ANA598 400 mg bid or placebo; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: ANA598 800 mg bid or placebo; Assigned to Arm(s): Cohort 3
D: Arm Label: SOF+RBV+placebo; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV, Drug: Placebo to match SOF, Drug: Placebo to match RBV | Arm Label: SOF+RBV; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV, SOF+RBV+placebo | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV, SOF+RBV+placebo | Intervention Type: DRUG; Name: Placebo to match SOF; Assigned to Arm(s): SOF+RBV+placebo | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): SOF+RBV+placebo

Answer: D